1. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta- analysis 
Rui Pedro Marques, Gonçalo S. Duarte, Carmelo Sterrantino, Helena Luna Pais, António Quintela, Ana Paula Martins, João Costa 
Critical Reviews in Oncology / Hematology 
Volume 118, Pages (October 2017)
DOI: /j.critrevonc
Copyright © 2017 Elsevier B.V. Terms and Conditions

2. Fig. 1
Flow chart.
Flow diagram illustrating flow of studies identified from the search strategy and reasons for exclusion.
Critical Reviews in Oncology / Hematology  , 54-62DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

3. Fig. 2
Main outcomes.
Aggregate results for the considered main outcomes: Overall Survival (OS), Progression Free Survival (PFS), Study withdrawals, Proportion of participants with grade ≥3 Adverse Events (AEs), and Total of grade ≥3 Adverse Events (AEs) reported. Horizontal lines represent 95% CIs.
Critical Reviews in Oncology / Hematology  , 54-62DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions

4. Fig. 3 Secondary outcomes.
Aggregate results for the considered additional outcomes: R0 resection rate, Metastases resection rate, Overall objective response rate, Complete response rate, Partial response rate, and Specific safety outcomes. Horizontal lines represent 95% CIs.
Critical Reviews in Oncology / Hematology  , 54-62DOI: ( /j.critrevonc )
Copyright © 2017 Elsevier B.V. Terms and Conditions